The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Ankylosing Spondylitis Resource Center
    • Gout Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Biosimilar Drugs Raise Questions around Treatment Efficacy, Quality, Safety

Biosimilar Drugs Raise Questions around Treatment Efficacy, Quality, Safety

April 20, 2017 • By Thomas R. Collins

  • Tweet
  • Email
Print-Friendly Version / Save PDF
kapona/shutterstock.com

kapona/shutterstock.com

WASHINGTON, D.C.—Challenges abound for the manufacturing of biosimilar drugs—from their sheer size compared with small molecule drugs to the unknowable proprietary aspects of the originator drugs—an expert said at the 2016 ACR/ARHP Annual Meeting in a session titled Immunology Update: Biologic Agents: From Nature to Protein Engineering to Biosimilars.

You Might Also Like
  • Biosimilars to Raise Unique Questions
  • Biosimilar Drugs Face Challenges to Reach the U.S. Market
  • FDA Proposes Adding Suffixes to Distinguish Biosimilar Drug Names
Explore This Issue
April 2017
Also By This Author
  • ACR Leaders Discuss E/M Coding Changes, Step Therapy & More

Above all, because biosimilars are copies of originator drugs that have been created out of living cells, they can never be identical. The question is how different they are, and how to assess and manage those differences and their relevance, if any, said John Isaacs, MD, director of the Institute of Cellular Medicine and professor of clinical rheumatology at Newcastle University, Newcastle upon Tyne, United Kingdom.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Clinicians should be aware of these challenges and other thorny issues surrounding these medications, Dr. Isaacs said. “These are biological drugs, and they’re produced by living cells. They have to be because they’re so complicated,” he said.

This means that post-translational modifications will affect the primary protein product, which are not always predictable and dependent, for example, with regard to the precise culture conditions of the cells producing the biosimilar. Further, every batch of a therapeutic antibody (biosimilar or originator) comprises multiple subtly different variants, which is known as microheterogeneity.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

“This is why biosimilars are not and cannot be identical to the originator in the same way as a chemically synthesized generic small-molecule drug can be identical to the original version of the drug,” Dr. Isaacs said.

The dawn of biosimilar drugs clearly brings the prospect for many advantages, he added. They’re far cheaper to develop because the regulatory process isn’t as lengthy, there’s less risk of failure in development, and the savings should mean wider availability of the drugs for patients. Developing a biosimilar can even lead to a greater understanding of the originator drug, because it becomes better characterized.

But process differences, including different cell lines and culture media, come with the potential for unpredicted effects, Dr. Isaacs said. These variables raise the prospect of immunogenicity, although not necessarily more immunogenicity.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

“There’s no reason why it should be more immunogenic,” he said. “It could be less immunogenic, which would be a good thing. The fact is, there are unknowns.”

Dr. Isaacs described these implications:

Registries and post-marketing surveillance: Because biosimilars are licensed after relatively few patient exposures, it is even more important to monitor their effects long term than it is for originators.

Pages: 1 2 3 | Single Page

Filed Under: Biologics & Biosimilars, Drug Updates, Meeting Reports Tagged With: 2016 ACR/ARHP Annual Meeting, American College of Rheumatology, biosimilar, Drugs, efficacy, patient care, Quality, Research, rheumatologist, rheumatology, Safety, therapyIssue: April 2017

You Might Also Like:
  • Biosimilars to Raise Unique Questions
  • Biosimilar Drugs Face Challenges to Reach the U.S. Market
  • FDA Proposes Adding Suffixes to Distinguish Biosimilar Drug Names
  • Report on EU’s Experience with Biosimilar Drugs Released: Will U.S. Experience Be Similar?

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2021 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.